Title: 

A method of predicting the severity of the course of SARS-Cov-2 viral infection in COVID-19 disease and a diagnostic test. 

Stage of protection: 

Patent No. Pat.241992 

Subject: 

The subject of the invention is a method of predicting the severity of the SARS-Cov-2 viral infection in patients with COVID-19 disease, by assessing the SARS-Cov-2 proliferative response of specific lymphocytes with the CD154/CD45 phenotype and a predictive diagnostic test using the mentioned method to assess survival of patients infected with SARS-Cov-2. 

Benefits: 

The introduction of a predictive diagnostic test will allow for a reduction in the costs and resources used by hospitals to select patients and, above all, patients from risk groups. 

Currently, there is no sensitive, specific and validated laboratory test performed using material collected from peripheral blood that would allow for a predictive diagnosis of the course of SARS-2-Cov-2 virus infection. 

The high specificity of monoclonal antibodies and the “nature” of the immune response to the antigen on which the test is based, determine the advantages of the presented method, which will certainly be characterized by high specificity and sensitivity. Both features are very important in the case of diagnostic tests. Another advantage of the method is a very short time to obtain the result confirming the diagnosis of the disease – approximately 48-72 hours – from the moment of collecting the material (whole blood taken from the antecubital vein with the anticoagulant lithium heparin) to obtaining the results. 

Stage of work: 

Validated, ready to use method. 

Application: 

Predictive diagnostic test for SARS-Cov-2 infection, selection of patients from selected risk groups of COVID-19 disease. 

Contact: 

@: sylwia.grzelak@umed.lodz.pl, tel.: 502 447 575